Lebrikizumab Vs Other Systemic Monotherapies for Moderate to Severe Atopic Dermatitis: Network Meta-Analysis of Short-Term Efficacy. J of Skin 2025, 9 (1), s517. https://doi.org/10.25251/skin.9.supp.517.